Skip to main content
Premium Trial:

Request an Annual Quote

StageZero Life Sciences, DiagnoseAtHome Partner on Multicancer Blood Test

NEW YORK — StageZero Life Sciences said on Wednesday that it has signed an agreement to offer its Aristotle multicancer blood test in the US and Canada through DiagnoseAtHome, an online provider of at-home health and lab testing services.

Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types including breast, liver, stomach, and bladder cancers in a single blood sample. The test is processed through StageZero's CLIA-certified lab.

Financial and other terms of the deal were not disclosed.

"Our partnership with DiagnoseAtHome allows greater access to early cancer screening for their many clients and broadens the availability of Aristotle in Canada and the USA," StageZero Chairman and CEO James Howard-Tripp said in a statement.

Earlier this year, Toronto-based StageZero closed a C$1.87 million (US$1.46 million) private financing.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.